![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TNIP3 |
Gene summary for TNIP3 |
![]() |
Gene information | Species | Human | Gene symbol | TNIP3 | Gene ID | 79931 |
Gene name | TNFAIP3 interacting protein 3 | |
Gene Alias | ABIN-3 | |
Cytomap | 4q27 | |
Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q96KP6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79931 | TNIP3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 1.28e-06 | 3.47e-01 | -0.0166 |
79931 | TNIP3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 1.96e-16 | 5.73e-01 | -0.0132 |
79931 | TNIP3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 3.96e-10 | 4.27e-01 | -0.013 |
79931 | TNIP3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 4.08e-07 | 4.10e-01 | -0.0121 |
79931 | TNIP3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.71e-02 | 5.99e-01 | -0.0961 |
79931 | TNIP3 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.73e-05 | 6.28e-01 | -0.0876 |
79931 | TNIP3 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.55e-03 | 6.58e-01 | -0.0822 |
79931 | TNIP3 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 6.98e-05 | 6.58e-01 | -0.0809 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00072495 | Lung | IAC | I-kappaB kinase/NF-kappaB signaling | 56/2061 | 281/18723 | 7.39e-06 | 2.62e-04 | 56 |
GO:00431226 | Lung | IAC | regulation of I-kappaB kinase/NF-kappaB signaling | 51/2061 | 249/18723 | 8.41e-06 | 2.87e-04 | 51 |
GO:00027643 | Lung | IAC | immune response-regulating signaling pathway | 70/2061 | 468/18723 | 4.79e-03 | 3.72e-02 | 70 |
GO:00022377 | Lung | IAC | response to molecule of bacterial origin | 56/2061 | 363/18723 | 5.78e-03 | 4.21e-02 | 56 |
GO:00324967 | Lung | IAC | response to lipopolysaccharide | 53/2061 | 343/18723 | 6.87e-03 | 4.75e-02 | 53 |
GO:004312213 | Lung | AIS | regulation of I-kappaB kinase/NF-kappaB signaling | 41/1849 | 249/18723 | 7.57e-04 | 1.08e-02 | 41 |
GO:000724913 | Lung | AIS | I-kappaB kinase/NF-kappaB signaling | 45/1849 | 281/18723 | 7.90e-04 | 1.11e-02 | 45 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNIP3 | SNV | Missense_Mutation | c.853N>A | p.Glu285Lys | p.E285K | Q96KP6 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
TNIP3 | SNV | Missense_Mutation | c.348N>T | p.Lys116Asn | p.K116N | Q96KP6 | protein_coding | deleterious(0) | possibly_damaging(0.785) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
TNIP3 | SNV | Missense_Mutation | novel | c.712N>T | p.Arg238Cys | p.R238C | Q96KP6 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-G4-6627-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
TNIP3 | SNV | Missense_Mutation | c.542G>T | p.Arg181Ile | p.R181I | Q96KP6 | protein_coding | deleterious(0.04) | possibly_damaging(0.466) | TCGA-G4-6628-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TNIP3 | SNV | Missense_Mutation | rs746466806 | c.1042N>A | p.Gly348Ser | p.G348S | Q96KP6 | protein_coding | tolerated(0.05) | benign(0.268) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNIP3 | SNV | Missense_Mutation | c.862T>G | p.Phe288Val | p.F288V | Q96KP6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
TNIP3 | SNV | Missense_Mutation | c.853G>A | p.Glu285Lys | p.E285K | Q96KP6 | protein_coding | deleterious(0) | possibly_damaging(0.535) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD | |
TNIP3 | SNV | Missense_Mutation | novel | c.994A>C | p.Lys332Gln | p.K332Q | Q96KP6 | protein_coding | tolerated(0.16) | benign(0.155) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
TNIP3 | SNV | Missense_Mutation | novel | c.1025G>A | p.Cys342Tyr | p.C342Y | Q96KP6 | protein_coding | tolerated(0.18) | benign(0.014) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
TNIP3 | SNV | Missense_Mutation | c.845N>G | p.Gln282Arg | p.Q282R | Q96KP6 | protein_coding | deleterious(0.04) | benign(0.187) | TCGA-A5-A0GB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |